双环醇对四环素诱发小鼠急性脂肪肝的保护作用

研究双环醇对四环素诱发小鼠急性脂肪肝的影响。小鼠一次腹腔注射四环素(180 mg·kg^-1) 24 h后，收集血样和肝组织，采用生化法测定肝脏甘油三酯(triglyceride，TG)、胆固醇(cholesterol，CHO)、谷胱甘肽(glutathione，GSH)含量，以及血清脂质和转氨酶水平；光谱法测定小鼠线粒体脂肪酸β-氧化速率以及肝脏极低密度脂蛋白(very low density lipoprotein，VLDL，TG)分泌速率。结果表明，双环醇(150及300 mg·kg^-1)连续灌胃给药3次可以不同程度地保护四环素引起的小鼠肝脏TG和CHO升高以及血清谷丙转氨酶(alanine aminotransferase，ALT)、谷草转氨酶(aspartate aminotransferase，AST)升高和脂质异常。双环醇(300 mg·kg^-1)还可减轻四环素诱发小鼠肝脏丙二醛(malondialdehyde，MDA)生成增加和GSH水平降低，并能抑制肝线粒体脂肪酸β-氧化速率下降。双环醇(300 mg·kg^-1)可部分逆转四环素所致小鼠肝脏VLDL(TG)分泌速率的减少。由此可见，双环醇对四环素诱发小鼠急性脂肪肝具有明显的保护作用，其作用机制与保护肝线粒体β-氧化功能、改善肝脂蛋白分泌及转运以及抑制肝脏脂质过氧化密切相关。     

小檗碱对2型糖尿病大鼠视网膜PPARα/δ/γ表达的影响

糖尿病视网膜病是最常见的糖尿病并发症之一，是导致失明的主要原因，因此有必要寻找新的治疗药物。给大鼠腹腔注射链脲菌素(35 mg·kg^-1) 2周后用高糖高脂饲料喂养14周，之后连续16周每天分别拌食给予小檗碱75、150及300 mg·kg^-1、非诺贝特100 mg·kg^-1和罗格列酮4 mg·kg^-1。用HE染色检查视网膜结构和免疫组化检测过氧化物酶体增殖物激活受体(PPARs) α/δ/γ的表达。结果发现，正常对照组大鼠的视网膜厚度大于其他各组，经小檗碱(150及300 mg·kg^-1)和罗格列酮(4 mg·kg^-1)的治疗能增加糖尿病大鼠视网膜的厚度，但视网膜的结构在各组间无差别；小檗碱(150及300 mg·kg^-1)和罗格列酮(4 mg·kg^-1)能明显降低糖尿病大鼠视网膜中PPARγ蛋白表达，小檗碱(150及300 mg·kg^-1)和非诺贝特(100 mg·kg^-1)能显著增加糖尿病大鼠视网膜中PPARα和PPARδ的表达。小檗碱调控视网膜PPAR α/δ/γ蛋白表达可能是其改善糖尿病视网膜病的机制之一，可能成为比罗格列酮和非诺贝特更有效的用于治疗糖尿病视网膜病的药物。     

联苯双酯对他克林引起的肝损伤的保护作用

目的　观察联苯双酯(DDB)对他克林(THA)诱发小鼠肝损伤的保护作用。方法　小鼠一次poTHA(56mg·kg^-1) ,观察12h内动物血清ALT ,肝脏MDA和动物体温的改变;分光光度法测定小鼠脑乙酰胆碱酯酶活性;酶动力法测定小鼠肝微粒体7-乙氧基香豆素脱乙基酶和UDP葡糖醛酸转移酶(UDPGT)的活性;荧光法测定线粒体膜电位的改变。结果　DDB 200 mg·kg^-1 可明显保护THA引起的小鼠体温下降、血清ALT和肝脏MDA的升高。DDB(100 μmol·L^-1 )可减轻THA造成的大鼠线粒体膜电位降低。DDB还可提高小鼠肝微粒体7-乙氧基香豆素脱乙基酶的活性,但对UDPGT无影响。结论　DDB似通过降低肝脏脂质过氧化反应、提高线粒体膜稳定性、调节THA代谢酶活性发挥其肝保护作用     

乌药叶提取物对高脂血症模型大鼠降脂作用以及肝脏LKB1-AMPK通路的影响

目的 考察乌药叶提取物对高脂血症大鼠模型降血脂作用以及对肝脏LKB1-AMPK通路相关蛋白表达的影响。方法 采用高脂饲料诱导的混合型高脂血症大鼠模型,以高、低剂量（1.6,0.8 g·kg^-1以生药量计）的乌药叶提取物灌胃,阳性药组给予非诺贝特20 mg·kg^-1,连续8周。分别在4,8周后检测血清中总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇（HDL-C）水平。实验末处死大鼠,解剖取肝脏,计算肝脏指数,油红O染色观察肝组织脂质蓄积程度,Western blotting检测肝脏LKB1-AMPK通路相关蛋白的表达。结果 连续给药4周,与模型组相比,阳性药组血清TG水平有显著降低（P<0.05）。连续给药8周,与模型组相比,高剂量组能显著降低血清中TC、TG、LDL-C的水平（P<0.01或P<0.05）。与对照组比,高、低剂量组和模型组肝脏指数均极显著升高（P<0.01）;与模型组比,高、低剂量组有降低的趋势,但差异无统计学意义。肝组织油红O染色结果显示,模型组肝细胞脂质蓄积严重,脂肪变性程度高,高剂量组肝细胞脂质蓄积和脂肪变性程度均有不同程度的改善。高、低剂量组均可显著提高模型大鼠肝脏AMPKα蛋白磷酸化水平。结论 乌药叶提取物能够降低血清脂质水平,改善肝细胞脂质蓄积,并且增加AMPKα蛋白磷酸化水平,激活AMPKα,从而促进脂质代谢。     

间硝苯地平在Beagle犬体内的药代动力学

目的用反相高效液相色谱法研究间硝苯地平(m-nifedipine，m-Nif)在Beagle犬体内的药代动力学特征。方法正交设计优化色谱分离条件，Beagle犬分别iv给予m-Nif 0.288 mg·kg^-1和ig m-Nif 1.152，3.456，10.370 mg·kg^-1。用反相高效液相色谱法分析血浆中原型药物浓度，血浆药物浓度-时间数据用3P97药代动力学软件分析。结果Beagle犬iv m-Nif，其体内过程符合二室模型，T_1/2β为116.8 min；ig给予m-Nif 后在Beagle犬体内的代谢符合一室模型，其中低剂量(1.152 mg·kg^-1)组C_max为20 μg·L^-1， T_1/2(k_e)为147 min；中剂量(3.456 mg·kg^-1)组C_max为36 μg·L^-1，T_1/2(k_e) 为122 min；高剂量(10.37 mg·kg^-1)组C_max为69 μg·L^-1，T_1/2(k_e)为144 min。结论Beagle犬ig和iv m-Nif 后，血浆中药物消除迅速，口服绝对生物利用度较低。     

重组小鼠β防御素3体内抗甲型流感病毒H1N1作用

目的 观察重组小鼠β防御素3(rMBD3)对甲型流感病毒感染小鼠的保护作用。方法 以10 mg·kg^-1·d^-1rMBD3腹腔注射3月,观察小鼠的一般状态,以及对主要脏器的影响。BALB/c小鼠,♀,分为正常对照组、模型对照组、rMBD3高剂量组(10 mg·kg^-1·d^-1)、rMBD3低剂量组(5 mg·kg^-1·d^-1)和利巴韦林组(100 mg·kg^-1·d^-1)。采用流感病毒液滴鼻感染建立甲型流感病毒H1N1感染小鼠模型,感染病毒12 h后分别腹腔注射给药。每日观察小鼠一般情况和死亡情况。于攻毒第3天检测肺泡灌洗液流感病毒滴度、血清γ干扰素含量、肺指数和肺组织病理变化。结果 小鼠腹腔注射10?mg·kg^-1·d^-1 rMBD3 3月,未发现明显异常反应或死亡,各重要脏器的未见明显病理改变。rMBD3各剂量组肺泡灌洗液中的病毒滴度、肺指数抑制率均降低,肺组织病理改变减少。结论 rMBD3对小鼠无明显毒性作用,在体内具有抗流感病毒、保护流感小鼠的活性。     

脑5-HT1A/1B、α2受体及腺苷酸环化酶参与了胍丁胺的抗抑郁作用

为了在单胺受体及受体后腺苷酸环化酶(adenylate cyclase,AC)水平探讨胍丁胺(agmatine,AGM)抗抑郁作用的精细机制,采用小鼠悬尾实验和强迫游泳实验观察AGM抗抑郁行为改变。采用放射免疫方法测定大鼠前额皮层突触膜蛋白AC活性。结果表明,AGM(5～40 mg·kg^-1,ig)在小鼠悬尾实验和强迫游泳实验模型上均有显著抗抑郁活性。同时伍用β受体/5-HT_1A/1B受体阻断剂吲哚洛尔(pindolol, PIN, 20 mg·kg^-1, ip)、 α₂肾上腺素受体拮抗剂育亨宾(yohimbine, YOH, 5～10 mg·kg^-1, ip)或咪唑克生(idazoxan, IDA, 4 mg·kg^-1, ip)对AGM(40 mg·kg^-1, ig)的抗抑郁活性具有显著拮抗效应; 而β受体阻断剂普萘洛尔(propranolol, PRO, 5～20 mg·kg^-1, ip)或5-HT₃受体拮抗剂曲匹西隆(tropisetron, TRO, 5～40 mg·kg^-1, ip)对AGM(40 mg·kg^-1, ig)的抗抑郁活性无显著影响。AGM(0.1～6.4 μmol·L^-1)与大鼠前额皮层提取的突触膜共孵可剂量依赖地激活AC活性, 而PIN(1 μmol·L^-1)或YOH(0.25～1 μmol·L^-1)均显著拮抗AGM(6.4 μmol·L^-1)对AC的激活作用; 慢性给予大鼠AGM(10 mg·kg^-1, ig, bid)或氟西汀(fluoxetine, FLU, 10 mg·kg^-1, ig, bid) 2 w也显著增强大鼠前额皮层基础及Gpp(NH)p 预激活的AC活性。本研究表明, 调节脑内5-HT_1A/1B和α₂等受体功能, 并激活前额皮层AC可能是AGM抗抑郁活性的重要机制之一。     

双去甲氧基姜黄素对肥胖模型小鼠糖脂代谢的影响及机制

目的 研究双去甲氧基姜黄素(bisdemethoxycurcumin,BDMC)对高糖高脂饮食诱导的肥胖小鼠胰岛素抵抗、糖脂代谢紊乱的影响,并探讨其机制。方法 C57BL/6小鼠40只随机分为正常组(10只)和高糖高脂饮食组(30只),正常组小鼠给予常规饲料,其余小鼠饲喂高糖高脂饮食诱导肥胖,造模8周。造模成功后,高糖高脂饮食组小鼠随机分为模型组、BDMC低剂量组(20 mg·kg^-1)、BDMC高剂量组(40 mg·kg^-1),每组10只。分别按剂量灌胃给药,每日1次,每周5次,连续8周。给药结束后,检测小鼠体质量、肝脏及脂肪重量,观察肝脏病理改变及脂质堆积情况,监测小鼠血糖、血脂、血清胰岛素等生化指标,并考察BDMC对TRPV1、AMPK及下游胰岛素信号、糖脂代谢通路的影响。结果 与正常组相比,模型组小鼠体质量及脏器指数增加,肝脏出现明显的病理改变,脂质堆积严重,血清胰岛素、血糖、血脂参数(TC、TG、LDL-C)显著增高,HDL-C显著降低;肝损伤(ALT、AST)加重;肝脏组织中TRPV1、SREBP、FAS蛋白表达显著升高,p-IRS1、p-AMPK、GLUT4、p-ACC表达显著降低。与模型组相比,给予BDMC治疗后,肝脏脂质堆积减少,组织病理改变得到改善,血糖、血清胰岛素、TC、TG、LDL-C、ALT、AST显著降低(P<0.05),HDL-C显著升高,肝脏中p-IRS1、p-AMPK、GLUT4、p-ACC表达升高,TRPV1、SREBP、FAS表达显著降低(P<0.05)。结论 BDMC能改善胰岛素抵抗,调节糖脂代谢紊乱,治疗高糖高脂饮食诱导的肥胖,其作用可能与调节TRPV1和AMPK信号通路有关。     

乌司他丁对脂多糖致小鼠急性肺损伤的保护作用以及与诱导型一氧化氮合酶和c-Jun表达的关系

目的探讨乌司他丁对脂多糖(LPS)致小鼠急性肺损伤的作用及其机制。方法小鼠腹腔注射乌司他丁(50和100 ku·kg^-1)或等体积生理盐水30 min后，分别静脉注射LPS 15 mg·kg^-1或等体积生理盐水，于注射LPS后不同时间检测有关各项指标。ELISA法测定血清和肺组织中TNFα水平，RT-PCR法测定TNFα mRNA和iNOS mRNA的表达。Western blotting法检测c-Fos，c-Jun及iNOS等蛋白表达。结果乌司他丁100 ku·kg^-1能显著降低LPS引起的小鼠的肺脏指数、肺组织及血清中NO水平的增加，下调肺组织c-Jun蛋白表达量和iNOS mRNA及其蛋白的表达量，而对小鼠的血清和肺组织冲洗液中TNFα含量以及肺组织MDA无明显影响。结论乌司他丁对LPS引起的小鼠肺损伤有保护作用，该作用与其抑制c-Jun蛋白和iNOS mRNA的表达有关。     

血清脂联素水平与冠状动脉粥样硬化程度的相关性

目的 探讨人血清脂联素水平与冠状动脉粥样硬化程度的关系。方法 根据冠状动脉造影结果和临床表现,将162例疑诊冠心病患者进行分组,用放射免疫法检测血清脂联素水平,同时测定患者血压、血脂、血糖等相关指标。结果 确诊冠心病患者血清脂联素水平(17.21±10.67 mg·L^-1)明显低于阴性对照组(32.94±15.18 mg·L^-1,P<0.01),脂联素水平随着动脉粥样硬化程度的加重呈进行性下降。血清脂联素水平与冠状动脉的狭窄程度、总胆固醇、甘油三酯、低密度脂蛋白胆固醇成负相关(P<0.01),与高密度脂蛋白胆固醇呈正相关(P<0.05)。结论 血清脂联素水平随动脉粥样硬化的发展呈进行性下降,有助于临床评价冠心病病变程度及其进展。     

木豆叶芪类提取物对雌激素缺乏性大鼠骨质丢失的影响

植物雌激素具有雌激素的抗骨丢失的作用，却没有雌激素的不良反应，因而受到广泛的重视。各国科学家都在积极寻找安全有效的、具有雌激素样作用的天然产物。已经发现的这类植物雌激素有异黄酮、木酚素、香豆素、二苯乙烯类等，在多种植物和中草药中均含有这些化合物。     

Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice

Bicyclol is used for the treatment of chronic hepatitis B in China. In this study, the effects of bicyclol (100 or 300 mg kg(-1), p.o.) on serum and liver lipid contents were investigated in both normal and experimentally induced hypercholesterolaemic mice. Hypercholesterolaemia was induced by either oral administration of cholesterol/bile salt or feeding a diet containing lard/cholesterol. Daily administration of bicyclol for 7 days dose-dependently increased the serum triglyceride level (29-80%) but slightly decreased the hepatic total cholesterol level (12-17%) in normal mice. Co-administration of bicyclol with cholesterol/bile salt decreased the hepatic triglyceride and total cholesterol levels (7-15% and 25-31%, respectively), when compared with the drug-untreated and cholesterol/bile salt-treated group. Bicyclol treatment for 7 days decreased hepatic triglyceride (5-76%) and total cholesterol (5-48%) levels in mice fed with high-fat/cholesterol diet. In contrast, bicyclol treatment increased the serum triglyceride level (18-77%) in mice treated with cholesterol/bile salt or fed with high-fat/cholesterol diet. Bicyclol treatment also caused an increase in hepatic index of normal and hypercholesterolaemic mice (3-32%). The results indicate that bicyclol treatment can invariably decrease hepatic lipid levels and increase serum triglyceride levels in normal and hypercholesterolaemic mice.     

Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice

The effects of schisandrin B (Sch B) on liver and serum lipid contents were investigated in mice with experimentally-induced hypercholesterolaemia. Hypercholesterolaemia was induced either by oral administration of a cholesterol/bile salts mixture (2/0.5 g kg(-1)) for four days or by feeding a high fat/cholesterol/bile salts (10/1/0.3%, w/w) diet for seven days. Daily co-administration of Sch B (50-200 mg kg(-1), i.g.) for four or six days, respectively, decreased hepatic total cholesterol (TC) and triglyceride (TG) levels (by up to 50% and 52%, respectively) in hypercholesterolaemic mice. Sch B treatment also increased hepatic indices (14-84%) in hypercholesterolaemic mice. The results indicated that Sch B treatment could decrease hepatic TC and TG levels, and increase liver weight, in mouse models of hypercholesterolaemia. Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice.     

Cholesterol-lowering effect of YM-16638 in cynomolgus monkeys

YM-16638 was found in preclinical studies to be an orally active leukotriene antagonist. Because LY-171883, another leukotriene receptor antagonist with a similar structure to YM-16638, showed a triglyceride-lowering effect with a peroxisomal proliferative effect in monkeys fed a normal diet, we investigated whether YM-16638 also showed a serum triglyceride-lowering effect by examining serum and hepatic lipid levels in cynomolgus monkeys fed a normal diet supplemented with YM-16638 for 4 weeks at a daily dose of 3.75 mg (8.5 μmole), 30 mg (67.7 μmole) or 60 mg (135.4 μmole)/kg body weight. Monkeys given YM-16638 showed a dose-dependent decrease in serum total cholesterol. At 2 weeks of treatment, serum LDL- and HDL-cholesterol in the YM-16638 group showed marked decreases of 35% and 32%, respectively. However, serum triglyceride levels did not change. By contrast, hepatic cholesterol and cholesterol ester levels in this group were only slightly increased, without any effect on hepatic triglyceride level. In vitro investigation of the effect of YM-16638 on LDL-receptor activity and mRNA expression in the human hepatoma cell line HepG2 cells showed that YM-16638 increased LDL-receptor activity in a dose-dependent manner at 44 h of treatment. mRNA level in these cells was also increased 1.7-fold at 8 h of treatment. These results suggest that the decrease in serum cholesterol level in monkeys treated with YM-16638 may be due to an increase in hepatic LDL-receptor activity. Furthermore, they suggest that YM-16638 may represent a potent hypocholesterolemic drug without serious side effects. © 1996 Wiley-Liss, Inc.     

金线莲甲醇提取物降脂作用研究

目的研究金线莲甲醇提取物对高血脂大鼠血脂及肝酯水平的影响。方法采用高脂饲料喂养致大鼠高脂血症模型,给予不同剂量的金线莲甲醇提取物给药后治疗,实验设正常组,模型组,辛伐他汀组,非诺贝特组和金线莲总膏高、中、低剂量(1 000、500、250 mg·kg-1)组,分别测定血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和肝脏组织匀浆中TC和TG的含量,并做肝脏病理学观察。结果金线莲总膏500、1 000 mg·kg-1剂量组可明显降低大鼠血清TC、TG和LDL-C的水平,并能显著提高血清HDL-C含量,其中高剂量组效果最好。另外高剂量组可显著降低肝脏TC和TG的水平。结论金线莲甲醇提取物在高血脂大鼠模型中具有显著地降血脂和肝脂作用。     

鸡骨草总黄酮碳苷对乙硫氨酸导致的小鼠脂肪肝的影响简

目的：研究鸡骨草总黄酮碳苷（AME）对乙硫氨酸（DL-E）所致小鼠脂肪肝的影响,并探讨其作用机制。方法：ICR小鼠随机分为4组：对照组,DL-E造模组,AME组和AME＋DL-E组,每组8只。用AME连续灌胃给予AME组和AME＋DL-E组小鼠7d,另外两组给予溶剂对照（三蒸水）,第7天灌胃给予DL-E组和AME＋DL-E组250mg／kgDL-E造模,其他两组给予溶剂对照（0．2％CMC-Na）。造模1h后再次灌胃给予所有小鼠AME或溶剂对照（三蒸水）,造模22h后收集血样和肝组织,采用生化法测定血清脂质和转氨酶水平,肝脏TG以及TC含量。采用实时定量PCR的方法测定肝脏中相关脂代谢基因水平。结果：AME可以显著减少小鼠肝脏脂肪空泡的数量和脂变的面积,降低TG和TC含量以及血清转氨酶水平。在脂质相关代谢基因的调控上,AME可以下调DL-E导致的固醇调节元件结合蛋白-1（Sterolregulatoryelementbind-ingprotein1,SREBP-1）、脂肪酸合成酶（Fattyacidsynthase,FAS）和乙酰辅酶A羧化酶（Aee-tyl-CoAcarboxylase1,ACCl）的高表达,并且AME可以逆转DL-E对过氧化物酶体增殖物活化受体α（Peroxisomeproliferatoractivativedre-ceptora,PPARα）和肉碱棕榈酰转移酶1α（Carnitinepalmitoyltransferase1α,CPT-1α）的抑制作用。结论：AME对DL-E引起的小鼠肝脏脂肪蓄积具有保护作用,并且这种作用主要是通过减少脂质合成,促进脂质氧化代谢来实现的。     

鬼针草总黄酮治疗血吸虫病肝纤维化的实验研究

目的:观察鬼针草总黄酮(total flavones of Bi-dens pilosa L,TFB)对血吸虫病肝纤维化的治疗作用。方法:将小鼠随机分为6组:正常对照组,模型组,治疗组(TFB57.5、115、230mg/kg)和秋水仙碱0.15mg/kg阳性药对照组(n=10)。除正常对照组外,其余各组每只小鼠经腹部皮肤感染日本血吸虫尾蚴诱导肝纤维化模型,并于感染6周后灌胃(i.g.)相应的受试药物,正常组和模型组小鼠灌胃等容量生理盐水,持续治疗8周。实验结束后,取小鼠血,测血清中ALT、AST、总蛋白(TP)及白蛋白(ALB)含量;取小鼠肝脾称重,计算肝、脾指数,并观察小鼠肝脏形态;同时取部分肝组织进行虫卵计数;另取固定部位肝组织作病理组织学检查。结果:TFB57.5mg/kg显著降低血吸虫病肝纤维化小鼠的肝、脾指数;TFB115、230mg/kg显著降低小鼠血清中ALT、AST、ALB含量;明显改善肝脏大体形态。病理组织学检测结果显示TFB115、230mg/kg明显改善血吸虫病肝纤维化小鼠肝组织结构,减轻肝纤维化程度,降低血吸虫肝纤维化小鼠病理评分。结论:TFB对血吸虫病肝纤维化有明显治疗作用。     

Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression

The objective of this study was to examine the therapeutic effect of osthol, an active constituent of Cnidium monnieri (L.) Cusson (Apiaceae), in hyperlipidemic fatty liver mice and investigate the potential mechanism of the osthol treatment. A mouse model with hyperlipidemic fatty liver was induced by orally feeding the fat milk for 4 weeks. The experimental mice were then treated with osthol 10-40 mg/kg for 6 weeks. After oral administration, the mice in the model and medicine-treated groups were continuously given the fat milk for 2 weeks again. Whereafter, the lipid levels in serum and liver, hepatic weight coefficient and histopathological evaluation were measured. The sterol regulatory element-binding protein (SREBP)-1c, SREBP-2, fatty acid synthase (FAS), low density lipoprotein (LDL) receptor and cholesterol 7α-hydroxylase (CYP7A) mRNA expressions in liver were examined. The results showed that in the osthol-treated groups, the total cholesterol, triglyceride and free fatty acid levels in serum and liver, and the hepatic weight coefficient were gradually decreased with dose. Importantly, the histopathological evaluation of liver specimens demonstrated that osthol might decrease lipid accumulation. Osthol could increase the mRNA expression of CYP7A and decrease the mRNA expressions of SREBP-1c, SREBP-2, FAS and LDL receptor in liver in fat milk-induced fatty liver mice. These results suggested that osthol might exert the therapeutic effect on fat milk-induced fatty liver in mice, by inhibiting hepatic SREBP-1c/2 mRNA expressions and subsequent modulation of SREBP-1c/2-mediated target genes such as FAS, CYP7A and LDL receptor.